Goldman Sachs started coverage on shares of NuVasive (NASDAQ:NUVA) in a research report released on Wednesday, Marketbeat.com reports. The brokerage issued a neutral rating and a $47.00 price target on the medical device company’s stock.
NUVA has been the topic of a number of other research reports. Morgan Stanley reissued an equal weight rating and set a $55.00 price objective (down previously from $67.00) on shares of NuVasive in a report on Tuesday, February 27th. Needham & Company LLC raised shares of NuVasive from an underperform rating to a buy rating and set a $71.00 target price on the stock in a report on Thursday, January 4th. BidaskClub raised shares of NuVasive from a strong sell rating to a sell rating in a report on Friday, March 2nd. Piper Jaffray reaffirmed a buy rating and issued a $90.00 target price on shares of NuVasive in a report on Tuesday, January 9th. Finally, Cowen set a $62.00 target price on shares of NuVasive and gave the company a buy rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $66.00.
NUVA stock opened at $54.42 on Wednesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.94 and a current ratio of 3.48. NuVasive has a twelve month low of $44.62 and a twelve month high of $81.68. The company has a market cap of $2,815.08, a price-to-earnings ratio of 28.49, a P/E/G ratio of 1.47 and a beta of 0.38.
In other news, CEO Gregory T. Lucier acquired 6,000 shares of the company’s stock in a transaction on Tuesday, March 6th. The shares were bought at an average cost of $50.30 per share, with a total value of $301,800.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Xact Kapitalforvaltning AB acquired a new position in NuVasive in the 4th quarter valued at $293,000. MetLife Investment Advisors LLC acquired a new position in NuVasive in the 4th quarter valued at $3,272,000. Westside Investment Management Inc. increased its stake in NuVasive by 76.0% in the 4th quarter. Westside Investment Management Inc. now owns 2,640 shares of the medical device company’s stock valued at $147,000 after buying an additional 1,140 shares during the period. Macquarie Group Ltd. acquired a new position in NuVasive in the 4th quarter valued at $19,094,000. Finally, Meadow Creek Investment Management LLC increased its stake in NuVasive by 22.0% in the 4th quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the medical device company’s stock valued at $429,000 after buying an additional 1,326 shares during the period.
ILLEGAL ACTIVITY WARNING: This story was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3340300/goldman-sachs-begins-coverage-on-nuvasive-nuva.html.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.